| 51 |
31884128 | Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI. | 2020 Feb |
2 |
| 52 |
31892990 | Inhibition of Tumor Lymphangiogenesis is an Important Part that EGFR-TKIs Play in the Treatment of NSCLC. | 2020 |
2 |
| 53 |
31897229 | SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells. | 2020 |
1 |
| 54 |
31898615 | T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors. | 2020 Jan-Feb |
1 |
| 55 |
31901678 | Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer. | 2020 May |
2 |
| 56 |
31904278 | Detection of EGFR T790M Mutation by Droplet Digital Polymerase Chain Reaction in Lung Carcinoma Cytology Samples. | 2020 Jan 6 |
2 |
| 57 |
31907582 | Cyclosporin A activates human hepatocellular carcinoma (HepG2 cells) proliferation: implication of EGFR-mediated ERK1/2 signaling pathway. | 2020 May |
3 |
| 58 |
31910497 | Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor. | 2020 Feb |
2 |
| 59 |
31922964 | Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment. | 2020 Mar |
1 |
| 60 |
31926441 | Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. | 2020 Mar |
4 |
| 61 |
31931029 | Disruption of the EGFR-SQSTM1 interaction by a stapled peptide suppresses lung cancer via activating autophagy and inhibiting EGFR signaling. | 2020 Apr 1 |
1 |
| 62 |
31931137 | Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. | 2020 May |
1 |
| 63 |
31932478 | EHD1 and RUSC2 Control Basal Epidermal Growth Factor Receptor Cell Surface Expression and Recycling. | 2020 Mar 16 |
1 |
| 64 |
31935369 | Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. | 2020 Jan 13 |
3 |
| 65 |
31942192 | Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis. | 2020 |
1 |
| 66 |
31943845 | Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. | 2020 Mar |
2 |
| 67 |
31945708 | Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. | 2020 Mar |
3 |
| 68 |
31945786 | Extreme Downregulation of Chromosome Y and Cancer Risk in Men. | 2020 Sep 1 |
1 |
| 69 |
31952541 | Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling. | 2020 Jan 17 |
1 |
| 70 |
31956415 | Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR-mutated lung adenocarcinoma: a report of two cases. | 2020 Mar |
3 |
| 71 |
31957595 | Relationship between epidermal growth factor receptor mutations and skin rash in non-small cell lung cancer patients. | 2020 Apr |
5 |
| 72 |
31959859 | Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib. | 2020 Jan 20 |
4 |
| 73 |
31964750 | Epidermal Growth Factor Receptor and Transforming Growth Factor β Signaling Pathways Cooperate To Mediate Chlamydia Pathogenesis. | 2020 Mar 23 |
2 |
| 74 |
31969600 | Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines. | 2020 Jan 22 |
2 |
| 75 |
31977865 | Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy: Study protocol clinical trial (SPIRIT Compliant). | 2020 Jan |
1 |
| 76 |
31982639 | Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. | 2020 Mar |
1 |
| 77 |
31985315 | Serum C-Reactive Protein Level Predicts Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. | 2020 Feb |
1 |
| 78 |
31988476 | Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling. | 2020 Dec |
1 |
| 79 |
31991049 | Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis. | 2020 Mar |
1 |
| 80 |
32000647 | Synthesis, Biological and Computational Evaluation of Novel 2,3-dihydro-2-aryl-4-(4- isobutylphenyl)-1,5-benzothiazepine Derivatives as Anticancer and Anti-EGFR Tyrosine Kinase Agents. | 2020 |
4 |
| 81 |
32005236 | Correction to: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. | 2020 Feb 1 |
1 |
| 82 |
32011193 | A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. | 2020 Jun |
1 |
| 83 |
32014348 | Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations. | 2020 May |
4 |
| 84 |
32017710 | Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. | 2020 May 1 |
1 |
| 85 |
32018052 | AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. | 2020 Jun |
1 |
| 86 |
32023774 | [The influence of TP53 mutation on the therapeutic effect of EGFR tyrosine kinase inhibitor and prognosis of EGFR mutant non-small cell lung cancer patients]. | 2020 Jan 23 |
2 |
| 87 |
32024694 | A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2). | 2020 Mar 13 |
1 |
| 88 |
32025485 | Use of a plasma test for verifying epidermal growth factor receptor gene (EGFR) mutations in fluid samples from non-small cell lung cancer patients. | 2020 |
4 |
| 89 |
32029440 | c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein. | 2020 May |
1 |
| 90 |
32053675 | Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. | 2020 |
2 |
| 91 |
32069320 | Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer. | 2020 |
2 |
| 92 |
32069373 | Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update. | 2020 Jun |
1 |
| 93 |
32070026 | Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET. | 2020 Feb 13 |
2 |
| 94 |
32201537 | CD148 Serves as a Prognostic Marker of Gastric Cancer and Hinders Tumor Progression by Dephosphorylating EGFR. | 2020 |
1 |
| 95 |
32439698 | AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. | 2020 Aug 15 |
1 |
| 96 |
32439863 | PPARδ is a regulator of autophagy by its phosphorylation. | 2020 Jun |
2 |
| 97 |
32692593 | Processing Temporal Growth Factor Patterns by an Epidermal Growth Factor Receptor Network Dynamically Established in Space. | 2020 Oct 6 |
1 |
| 98 |
32860853 | Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth. | 2020 Nov 28 |
1 |
| 99 |
33000220 | Gangliosides and CD82 inhibit the motility of colon cancer by downregulating the phosphorylation of EGFR at different tyrosine sites and signaling pathways. | 2020 Nov |
1 |
| 100 |
33179922 | Phosphorylation-Dependent Conformations of the Disordered Carboxyl-Terminus Domain in the Epidermal Growth Factor Receptor. | 2020 Dec 3 |
1 |